Document

NEW YORK, November 5, 2021 (GLOBE NEWSWIRE) – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal first quarter ended September 30, 2021. Immunovant ended the quarter with approximately $559 million in cash.

R&D Expenses: Research and development expenses were $21.4 million for the three months ended September 30, 2021, compared to $12.0 million for the three months ended September 30, 2020. The year-over-year increase primarily reflected higher contract manufacturing costs and personnel-related expenses (including stock-based compensation), reflecting investment spending to support our strategic objectives as we prepare to re-initiate our clinical activities. These increases were partially offset by lower program-specific clinical trial activities due to the continued voluntary pause.

G&A Expenses: General and administrative expenses were $16.3 million for the three months ended September 30, 2021, compared to $9.0 million for the three months ended September 30, 2020. The year-over-year increase was primarily due to financial advisory fees, legal and other professional costs and higher personnel-related expenses (including stock-based compensation).

Net Loss: Net loss was $37.7 million ($0.35 per common share) for the three months ended September 30, 2021, compared to $20.8 million ($0.25 per common share) for the three months ended September 30, 2020. Net loss for the three months ended September 30, 2021 and 2020 included $8.4 million and $3.4 million, respectively, related to non-cash stock-based compensation expense.

R&D Expenses: Research and development expenses were $40.1 million for the six months ended September 30, 2021, compared to $28.9 million for the six months ended September 30, 2020. The year-over-year increase primarily reflected higher personnel-related expenses (including stock-based compensation), increases in clinical studies and clinical research and higher contract manufacturing costs, reflecting investment spending to support our strategic objectives as we prepare to re-initiate our clinical activities. These increases were partially offset by lower program-specific clinical trial activities due to the continued voluntary pause.

G&A Expenses: General and administrative expenses were $27.5 million for the six months ended September 30, 2021, compared to $18.7 million for the six months ended September 30, 2020. The year-over-year increase was primarily due to financial advisory fees, legal and other professional costs and higher personnel-related expenses (including stock-based compensation).

Net Loss: Net loss was $68.2 million ($0.66 per common share) for the six months ended September 30, 2021, compared to $47.5 million ($0.61 per common share) for the six months ended September 30, 2020. Net loss for the six months ended September 30, 2021 and 2020 included $12.2 million and $7.3 million, respectively, related to non-cash stock-based compensation expense.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401 (“batoclimab”), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include Immunovant’s plan to develop batoclimab across a broad range of autoimmune indications. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidate, including the timing of the commencement of additional clinical trials and resumption of current trials; Immunovant’s scientific approach, clinical trial design, indication selection and general development progress; future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this

press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidate may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of the ongoing COVID-19 pandemic on Immunovant’s clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval and commercialization of its sole product candidate, batoclimab; Immunovant is at an early stage in development of batoclimab; and Immunovant will require additional capital to fund its operations and advance batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s most recent Annual Report on Form 10-K, its Form 10-Q to be filed with the SEC on November 5, 2021, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


	Three Months Ended September 30,						Six Months Ended September 30,
	2021			2020			2021			2020
Operating expenses:
Research and development	$		21,361	$		11,976	$		40,066	$		28,898
General and administrative	16,289			8,998			27,469			18,662
Total operating expenses	37,650			20,974			67,535			47,560
Other expense (income), net	84			(225)			711			(151)
Loss before (benefit) provision for income taxes	(37,734)			(20,749)			(68,246)			(47,409)
(Benefit) provision for income taxes	(31)			40			(72)			88
Net loss	$	(37,703)		$	(20,789)		$	(68,174)		$	(47,497)
Net loss per common share – basic and diluted	$	(0.35)		$	(0.25)		$	(0.66)		$	(0.61)
Weighted-average common shares outstanding – basic and diluted	109,078,427			84,353,438			103,558,036			77,623,132


	September 30, 2021		March 31, 2021
Assets
Current assets:
Cash	$	558,952	$	400,146
Prepaid expenses and other current assets	4,840		8,860
Total current assets	563,792		409,006
Operating lease right-of-use assets	2,731		3,282
Property and equipment, net	209		201
Total assets	$	566,732	$	412,489
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	4,243	$	2,432
Accrued expenses	23,058		15,160
Current portion of operating lease liabilities	1,082		1,179
Total current liabilities	28,383		18,771
Operating lease liabilities, net of current portion, and other noncurrent liabilities	1,952		2,238
Total liabilities	30,335		21,009
Commitments and contingencies
Stockholders’ equity:
Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at September 30, 2021 and March 31, 2021	—		—
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2021 and March 31, 2021	—		—
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 114,998,871 shares issued and outstanding at September 30, 2021 and 500,000,000 shares authorized, 97,971,243 shares issued and outstanding at March 31, 2021	12		10
Additional paid-in capital	802,774		590,425
Accumulated other comprehensive income (loss)	442		(298)
Accumulated deficit	(266,831)		(198,657)
Total stockholders’ equity	536,397		391,480
Total liabilities and stockholders’ equity	$	566,732	$	412,489